Molina Healthcare, Inc. (MOH) Balance Sheet

The trajectory here appears to be one of shrinking capital cushion rather than outright balance sheet stress; total assets have oscillated in a fairly narrow $15.2B–$16.4B band, but liabilities grew from $10.3B in 2024Q2 to $11.5B in 2026Q3, an increase of roughly 11.6%, while equity moved in the opposite direction. This suggests the liability side — dominated by claims reserves and payables — is expanding even as the top line contracts, which would be consistent with the medical cost trend outpacing state rate resets flagged in the prior income statement analysis. Investors should monitor whether the equity ratio stabilizes in coming quarters, as continued compression from a 26.7% base could eventually constrain statutory headroom in states with minimum capital requirements.

The $1.8 billion decline in claims reserves between 2025Q3 and 2025Q4 is difficult to reconcile with the 101.4% combined ratio reported in the same period; a combined ratio above 100% would normally imply that current-period medical spend exceeded earned premium, not that prior-period obligations shrank by nearly 17%. This pattern may reflect a favorable prior period development release that propped up 2025Q4 earnings, though the absence of an explicit PPD disclosure in the supplied data means this warrants closer reading of the statutory filings. Reserve levels relative to the roughly $9.7 billion of claims paid in 2026Q3 suggest coverage of approximately one year of payouts, which appears adequate for a short-tail Medicaid book, but the volatility argues that reserve estimation remains a meaningful earnings swing factor.

With ROE falling from 6.8% in 2024Q3 to 0.9% in 2026Q3, the equity base is now being depleted from two directions simultaneously — reduced retained earnings and active buybacks — while the liability side continues to grow. The buyback program was notably funded through investment portfolio sales rather than operating cash flow, per the prior cash flow analysis, which means Molina was converting liquid assets into capital returns at a time when underwriting profitability was deteriorating. This sequencing appears difficult to sustain if the combined ratio stays near 99%; a prolonged period above that level could force either a pause in repurchases or incremental capital raising at unfavorable terms, and the debt-to-equity ratio of roughly 0.97x leaves some, but not unlimited, room to lever.

As is typical for a managed care organization, the reserve line dwarfs all other liability categories, which means liquidity adequacy hinges almost entirely on claims payment timing rather than on traditional working capital mechanics. The $9.7 billion of claims paid in 2026Q3 against a $9.7 billion reserve balance implies reserves are covering close to one quarter of payout velocity at current run-rate, which appears reasonable for a Medicaid book with predictable short-tail dynamics. However, the supplied data does not disclose days-claims-payable or reinsurance recoverables, so the quality of this liquidity profile cannot be fully assessed from the balance sheet alone; a material deterioration in DCP would be an early warning that current-period reserves are being stretched thin to support reported earnings.